Innovative pharma contracts: When do value-based arrangements work?
Many are exploring alternatives to traditional ‘per pill’ arrangements underlying reimbursement. This holds implications for pharma manufacturers.
Many are exploring alternatives to traditional ‘per pill’ arrangements underlying reimbursement. This holds implications for pharma manufacturers.
Source: McKinsey

Innovative pharma contracts: When do value-based arrangements work?